Thursday, November 19, 2026 Updated Briefings Saved 中文
AI Daily Radar

AI and the frontier tech around it, explained every morning

Isomorphic Labs raises $5B Series C to push drugs toward trials

Photo: 4339272 / Pixabay

Isomorphic Labs, the AI drug-discovery company spun out of Google’s DeepMind and now part of Alphabet, raised $5 billion in a Series C round, six months after a $2.1 billion round. The company, led by Demis Hassabis, plans to use the capital to push its drug pipeline toward clinical trials; it has no approved drugs yet. The report did not identify investors, a valuation, specific drug candidates, or trial start dates.

Verified and unconfirmed

  • Verified: The report states that Isomorphic Labs raised a $5 billion Series C, six months after a $2.1 billion round, and plans to use the funds to push its drug pipeline toward clinical trials.
  • Not yet confirmed: The report does not disclose the investors, valuation, specific pipeline candidates, or any trial start dates.

Background

Isomorphic Labs was spun out of Google’s DeepMind in 2021 and is part of Alphabet; Demis Hassabis leads the company. AI drug discovery uses machine-learning models to propose and prioritize molecules that still require laboratory and clinical validation, a long and expensive process.

Why it matters

The round gives Isomorphic a larger financial runway to fund preclinical work and early clinical testing, but because no candidate or trial date has been named, the move into human trials remains a goal rather than a scheduled step.

What to watch

Watch for Isomorphic to name a specific drug candidate and disclose an investigational new drug (IND) filing or a Phase 1 trial start, which would show the pipeline has moved from computational work into clinical testing.

Coverage of this story

Comments

Comments

Comments use a GitHub account and are moderated. Comment rules

More in AI

See all